Rockwell Automation today announced support for the National Association of Manufacturers' Vaccine Acceptance Campaign, “This Is Our Shot.” Last month, the campaign launched a public service announcement and website to educate and encourage manufacturing team members, their families, and communities to consider getting a COVID-19 vaccine when available.
Takeda has been named a Global Top Employer for 4th consecutive year! We are especially proud of this recognition because, in 2020, everything changed. Except our patients’ need for innovative treatments and therapies. Except your dedication to your work and our purpose. And except our commitment to your career – as recognized by this award. We look forward to building on this achievement and sharing positive work experiences with you throughout 2021.
Though National Cancer Prevention Month has come to an end, Alkermes will not stop working to uncover potential new cancer immunotherapies. Share these tips that may help reduce the risk of cancer and help spread awareness.
At Alexion, Corporate Social Responsibility (CSR) is an inherent part of everything we do and supports our mission to transform the lives of people affected by rare diseases and devastating conditions. In addition to developing and delivering life-changing medicines, this mission drives us to seek opportunities to advance innovative solutions to system-wide challenges faced by rare disease patients, such as the “diagnostic odyssey.”
NEW YORK, February 12, 2021 /3BL Media/ - Today, Comcast NBCUniversal announced the launch of Plan Your Vaccine, a nationwide awareness campaign, website and interactive tool that will provide the latest news and information about when and where people can receive the COVID-19 vaccine.
Top industry leaders and venture firms unite behind Ukko’s efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten
Palo Alto /Tel Aviv / Leverkusen, January 27, 2021 /3BL Media/ – Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, today announced USD 40 million in new Series B funding. Ukko harnesses artificial intelligence (AI) and protein engineering to develop healthier food and therapies for food allergies. The new funding will allow Ukko to enter clinical trials with its investigational therapeutic for peanut allergies. It will also accelerate development of Ukko’s gluten that is designed for people with celiac and other gluten sensitivities.
by Noel Maestre, PE, LEED AP SlateXpace Director, and Peter Walters, Director of ATMPs
Facing pressure in the ATMP marketplace? Multimodal manufacturing is your solution for that.
Pharmaceutical developers have always been history-makers. In the 18th and 19th centuries, they gave us the world’s first vaccines. In the 1980s, they ushered in the golden age of recombinant therapeutic proteins. Today, they’ve brought us to the doorstep of advanced therapy medicinal product (ATMP) manufacturing, which is an idea that could transform how we approach the complex health needs of a global population.